Dr. Daniel W. Coyne, MD

Dr. Coyne practices at Debaliviere Dialysis in Saint Louis, Missouri.

Dr. Coyne's NPI, 1427074749, was assigned on July 14, 2006. Dr. Coyne graduated from Cleveland Medical College, Homeopathic in 1983. Dr. Coyne holds Missouri license R6J62.

Dr. Coyne's primary practice is Debaliviere Dialysis, at 4950 Childrens Pl, Saint Louis, MO 63110 in Saint Louis City. The practice phone is (314) 367-9111.

Dr. Coyne's primary practice is Debaliviere Dialysis in Saint Louis, Missouri. The medical group on file is WashU Medicine Psychiatry. Dmand AI also links Dr. Coyne to 3 more dialysis centers and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Coyne practices, 4 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Coyne's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Coyne is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Coyne's licenses on file in 3 states: Missouri, Ohio and Georgia.

Dmand AI lists acute kidney failure, chronic kidney disease, fluid and electrolyte imbalances and kidney disease among the conditions Dr. Coyne treats.

CMS data shows 350 Medicare services from Dr. Coyne across 5 procedure codes in 2024, for 89 Medicare patients. Medicare paid $76,851 for them.

CMS counts 89 Medicare patients who saw Dr. Coyne in 2024. The largest group is under 65, with 57 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 62% are also on Medicaid. Their average risk score is 9.37, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Coyne's median patient age at 63, with 42% women.

In 2024, Dr. Coyne wrote 1,513 Medicare Part D claims for 198 patients. 86% of them were for generic drugs. CMS names the drug for 1,300 of them, across 42 drugs with 11 or more claims each, at $282,779 in total drug cost. In 2023, CMS named 2,345 claims across 54 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Coyne for performance year 2024, reported as part of a group. Dr. Coyne accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 131 papers to Dr. Coyne, published from 2005 to 2024. 2014 was the busiest year, with 7. The most frequent topics are Renal Dialysis, Kidney Failure, Chronic and Ferric Compounds. Dr. Coyne has published most often in Kidney Int. Dr. Coyne's most frequent co-authors are Rajiv Agarwal, MD, Steven N. Fishbane, MD and Stuart M. Sprague, DO.

Dmand AI links Dr. Coyne to 6 clinical trials, 2 of them phase 3 studies. Conditions studied include Renal Insufficiency, Chronic, Renal Insufficiency and Acute Kidney Injury. GlaxoSmithKline sponsors the most, 2. Open Payments lists research payments to Dr. Coyne that name 1 trial.

CMS Open Payments shows 511 general payments to Dr. Coyne from 24 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 37% of the total. Fresenius USA Marketing, Inc. paid the most, $275,457. It also lists 11 research payments totaling $1,812 in 2016, naming 1 clinical trial.

Dr. Coyne graduated from Cleveland Medical College, Homeopathic in 1983.

Dr. Coyne is in network with 15 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.